Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Hypothalamic–Pituitary Alterations in Patients With Neurosarcoidosis

View through CrossRef
Sarcoidosis is a non-caseating, granulomatous inflammatory disorder that can affect the central nervous system (CNS), including the hypothalamic–pituitary region, although rarely. The clinical manifestations of hypothalamic–pituitary neurosarcoidosis are heterogeneous and require a prompt diagnosis to ensure the most appropriate treatment. We have reviewed the cases of neurosarcoidosis affecting the hypothalamic–pituitary axis published since 2002 and compared them with the cases reported in the literature up to 2002, which were previously meta-analysed by our research group. Since 2002, 64 cases were identified in the literature: 37 cases presented with diabetes insipidus, 36 were found to have secondary amenorrhoea, 30 with hypogonadotropic hypogonadism, 17 with hyperprolactinaemia, 15 with thyroid-stimulating hormone deficiency, and 8 cases of panhypopituitarism. Uncommon manifestations included hyperphagia, sudden death, and thermodysregulation. We confirm that neurosarcoidosis affecting the hypothalamic–pituitary axis is an uncommon manifestation of sarcoidosis. Neither changes in the clinical manifestations and diagnosis nor significantly novel management options have appeared in the last decade. While it is a rare disorder, the involvement of the CNS is an indication to treat sarcoidosis and as the symptoms of CNS involvement, including hypothalamic–pituitary alterations, may precede the diagnosis of sarcoidosis, it is important to include neurosarcoidosis in the differential diagnosis of hypothalamic–pituitary axis dysfunction in order to facilitate prompt and appropriate treatment.
Title: Hypothalamic–Pituitary Alterations in Patients With Neurosarcoidosis
Description:
Sarcoidosis is a non-caseating, granulomatous inflammatory disorder that can affect the central nervous system (CNS), including the hypothalamic–pituitary region, although rarely.
The clinical manifestations of hypothalamic–pituitary neurosarcoidosis are heterogeneous and require a prompt diagnosis to ensure the most appropriate treatment.
We have reviewed the cases of neurosarcoidosis affecting the hypothalamic–pituitary axis published since 2002 and compared them with the cases reported in the literature up to 2002, which were previously meta-analysed by our research group.
Since 2002, 64 cases were identified in the literature: 37 cases presented with diabetes insipidus, 36 were found to have secondary amenorrhoea, 30 with hypogonadotropic hypogonadism, 17 with hyperprolactinaemia, 15 with thyroid-stimulating hormone deficiency, and 8 cases of panhypopituitarism.
Uncommon manifestations included hyperphagia, sudden death, and thermodysregulation.
We confirm that neurosarcoidosis affecting the hypothalamic–pituitary axis is an uncommon manifestation of sarcoidosis.
Neither changes in the clinical manifestations and diagnosis nor significantly novel management options have appeared in the last decade.
While it is a rare disorder, the involvement of the CNS is an indication to treat sarcoidosis and as the symptoms of CNS involvement, including hypothalamic–pituitary alterations, may precede the diagnosis of sarcoidosis, it is important to include neurosarcoidosis in the differential diagnosis of hypothalamic–pituitary axis dysfunction in order to facilitate prompt and appropriate treatment.

Related Results

A comprehensive diagnostic approach in suspected neurosarcoidosis
A comprehensive diagnostic approach in suspected neurosarcoidosis
AbstractNeurosarcoidosis presents a diagnostic challenge in clinical settings, as it has no pathognomonic symptoms or signs and a wide range of differential diagnoses. The aim of t...
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
I am writing this letter to address an increasingly high-risk but under-explored complication of pituitary apoplexy in patients who have contracted COVID-19. In light of recent res...
Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Abstract Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tumor-...
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
<div>Abstract<p>Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tu...
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
<div>Abstract<p>Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tu...
Abstract 739: Increased mortality in patients with pituitary adenomas
Abstract 739: Increased mortality in patients with pituitary adenomas
Abstract Purpose: To evaluate mortality rate and causes of death in patients with pituitary adenomas. Material & Methods: Five hundred seventy-two patients with ...
Molecular pathogenesis of pituitary tumours
Molecular pathogenesis of pituitary tumours
Abstract Pituitary adenomas are discovered in up to 25% of unselected autopsies, however, clinically apparent tumours are considerably less common. The pituitary gla...

Back to Top